Sharda Cropchem Q1 Review - Healthy Revenue Growth Offset By Adverse Margins: Prabhudas Lilladher

BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy..Prabhudas Lilladher Report.Sharda Cropchem Ltd. reported strong revenue growth of 32% YoY in Q1 FY23. However, adverse currency impact coupled with increased freight cost has in turn resulted into an overall miss into estimates. Key highlights are:volume/price/forex growth of down 2.5%/up 38%/down 3.3% YoY respectively;Sharda Cropchem's gross margins contracted by 390 basis points YoY to 25.4% largely led by adverse forex impact (euro/U.S. dollar depreciated by 7% during Q1);while higher freight cost coupled with higher legal and professional charges and one-off impact of Rs 121.5 million pertaining to loss on fair value of investments has resulted into an Ebitda margin contraction of 480 bps YoY to 11.7% (including IU&AD write-off of Rs 28 million) andworking capital days up by three days YoY to 91..Click on the attachment to read the full report:.DISCLAIMERThis report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime..Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Sharda Cropchem Q1 Review - Healthy Revenue Growth Offset By Adverse Margins: Prabhudas Lilladher

Sharda Cropchem Q1 Review - Healthy Revenue Growth Offset By Adverse Margins: Prabhudas Lilladher

Choose a plan